Compare iShares Core High Dividend ETF (HDV) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Repligen Corporation Common Stock — how do they compare? iShares Core High Dividend ETF trades at $29.57 (market cap $15.11B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: iShares Core High Dividend ETF is the larger of the two by market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 118 Days and Repligen Corporation Common Stock for 0 Days on average.
| HDV | RGEN | |
|---|---|---|
Market Cap | $15.11B | $11.14B |
Volume | 2,559,662 | 1,259,263 |
52-Week High | $29.93 | $194.57 |
52-Week Low | $23.64 | $102.87 |
Typical Hold Time | 118 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $29.15, up 0.28% with a bullish technical signal from moving averages. The ETF recently underwent a significant sector rebalance, reducing healthcare exposure while increasing energy, staples, and utilities. Technical indicators show strong momentum with RSI at 66.71 suggesting neutral conditions, while ADX readings indicate a strong trend. Recent dividend distributions of $0.10 and $0.06 demonstrate the fund's income-focused strategy.
The ETF's concentrated sector allocation (62% in three sectors) presents both opportunity and risk. While the 3% yield attracts income investors, the reduced diversification may increase vulnerability to sector-specific headwinds. Technical strength supports near-term upside, but investors should weigh the trade-off between current income and long-term growth potential given the sector concentration.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
